key: cord-0068250-ar9oe0as authors: Biasco, Luigi; Klersy, Catherine; Beretta, Giulia S; Valgimigli, Marco; Valotta, Amabile; Gabutti, Luca; Bruna, Roberto Della; Pagnamenta, Alberto; Tersalvi, Gregorio; Ruinelli, Lorenzo; Artero, Andrea; Senatore, Gaetano; Jüni, Peter; Pedrazzini, Giovanni B title: Comparative frequency and prognostic impact of myocardial injury in hospitalized patients with COVID-19 and Influenza date: 2021-08-30 journal: Eur Heart J Open DOI: 10.1093/ehjopen/oeab025 sha: 78411485881c5ffe1fc014bf528b6a0fea3ea74a doc_id: 68250 cord_uid: ar9oe0as AIMS: Myocardial injury (MINJ) in Coronavirus disease 2019 (COVID-19) identifies individuals at high mortality risk but its clinical relevance is less well established for Influenza and no comparative analyses evaluating frequency and clinical implications of MINJ among hospitalized patients with Influenza or COVID-19 are available. METHODS AND RESULTS: Hospitalized adults with laboratory confirmed Influenza A or B or COVID-19 underwent highly-sensitive cardiac T Troponin (hs-cTnT) measurement at admission in four regional hospitals in Canton Ticino, Switzerland. MINJ was defined as hs-cTnT >14 ng/L. Clinical, laboratory and outcome data were retrospectively collected. The primary outcome was mortality up to 28 days. Cox regression models were used to assess correlations between admission diagnosis, myocardial injury and mortality. Clinical correlates of MINJ in both viral diseases were also identified. MINJ occurred in 94 (65.5%) out of 145 patients hospitalized for Influenza and 216 (47.8%) out of 452 patients hospitalized for COVID-19. Advanced age and renal impairment were factors associated with myocardial injury in both diseases. At 28 days, 7 (4.8%) deaths occurred among Influenza and 76 deaths (16.8%) among COVID-19 patients with a hazard ratio (HR) of 3.69 (95%-CI 1.70-8.00). Adjusted Cox regression models showed admission diagnosis of COVID-19 [HR:6.41 (95%-CI 4.05-10.14)] and MINJ [HR:8.01 (95%-CI 4.64-13.82)] to be associated with mortality. CONCLUSIONS: Myocardial injury is frequent among both viral diseases and increases the risk of death in both COVID-19 and Influenza. The absolute risk of death is considerably higher in patients admitted for COVID-19 as compared with Influenza. Hospital, Ontario COVID-19 Science Advisory Table, Department like symptoms to severe respiratory distress syndromes 1-3 , whereas advanced age and preexisting 66 cardiovascular diseases have been identified as predisposing factors for mortality in both viral 67 diseases 4-8 . 68 The occurrence of myocardial injury (MINJ) has been previously recognized as prognostic marker 69 in hospitalized patients affected by different respiratory illnesses such as pneumonia, chronic 70 obstructive pulmonary disease (COPD), sepsis and acute respiratory distress syndrome (ARDS) [9] [10] [11] . 71 MINJ similarly occurs in COVID-19 patients, and while its mechanism is poorly understood 12, 13 , 72 studies have confirmed its negative prognostic role 12, 14-17 . 73 Several similarities and differences have been drawn between Influenza and COVID-19 both from 74 clinical and prognostic perspectives 18 . 75 Influenza and COVID-19 are both contagious respiratory viral illnesses with a relevant virulence 76 able to cause pandemic events. Both clinical entities have been often compared on a clinical 77 ground, 19 and initial autoptic comparative studies have highlighted how specific pathophysiological 78 mechanisms are shared between the two viral infections 20 . One of the multiple aspects linking the 79 severe acute respiratory syndrome coronavirus-2 (SARS-COV2) and Influenza viruses is 80 represented by the peculiar endothelial involvement leading to microvascular thrombosis and neo- 81 angiogenesis, 20 which might represent the mechanisms behind MINJ. 82 Thus, comparisons between COVID-19 and other viral disease might provide clinically relevant 83 information confirming the hypothesis that presence of myocardial injury has a prognostic 84 relevance in different viral diseases. It is in fact unknown whether MINJ occurs in COVID-19 with 85 similar rates also in other viral respiratory diseases such as Influenza 21-24 and no study has assessed 86 the comparative prognostic role of MINJ for mortality in COVID-19 and Influenza patients. 87 Thus, the aim of the following analysis is to provide comparative frequency rates and prognostic obtained by means of a chemiluminescent emission which is measured by a photomultiplier. 141 Myocardial injury was defined as hs-cTnT level above the upper reference limit (99th percentile) 142 for the normal population. The cut off of hs-cTnT ≤14 ng/L and >14 ng/L was used to discriminate 143 between absence and presence of myocardial injury. Normal ranges of laboratory values are 144 reported in Table S1 . 145 The primary outcome was all-cause mortality up to 28 days, secondary outcomes were admission to 146 an intensive care unit, mechanical ventilation or mechanical hemodynamic support, length of in-147 hospital stay in both cohorts. Statistical analysis 149 We report medians and interquartile ranges (IQR) for continuous variables and counts and percent 150 for categorical variables. The Mann Whitney U test and the Fisher exact test were used for between-151 group comparisons. Missing values were imputed using chained equations multiple imputations. 152 Five datasets were generated, using all common variables to both cohorts, including clinical 153 outcomes. Table S2 presents the frequency of missing covariate data. 154 We estimated the propensity of being hospitalized with COVID-19 based on a logistic regression 155 model that included all baseline characteristics, to enable analyses weighted by the inverse 156 probability of the admission diagnosis and adjust analyses for differences in clinical and laboratory 157 characteristics at admission between COVID-19 and Influenza patients. The statistical efficacy of 158 the procedure was assessed by comparing standardized differences in arithmetic means or 159 proportions between patients admitted for influenza and COVID-19 before and after inverse-160 probability weighing 25 . 161 We calculated mortality rates per 100 person-weeks with 95% confidence intervals (95%-CI) and 162 plotted time-to-event curves for mortality up to 28 days using Kaplan-Meier estimates. Time-to-163 7 event curves were plotted separately for patients with Influenza and COVID-19 by presence of 164 myocardial injury (hs-cTnT≤ versus >14 ng/L) and compared using a log-rank test. 165 Primary analyses were based on Cox regression models weighted for the inverse probability of the COVID-19 (rate 4.7 per 100 patients per week, 95% CI 3.7-5.9), for an unadjusted hazard ratio 249 (HR) of 3.69 (95%-CI 1.70 to 8.00). 250 In patients with Influenza, all deaths were recorded among patients with baseline hs-cTnT >14 ng/L 251 (1.9 per 100 patients per week, 95%-CI 0.9-4.1). 252 In patients with COVID-19, 64 deaths occurred among those with baseline hs-cTnT >14 ng/L (9.2 253 per 100 patients per week, 95%-CI 7.2-11.7), whereas 12 deaths occurred in those without hs-cTnT 254 elevations (1.3 per 100 patients per week, 95%-CI 0.7-2.3). Mortality at 28 days was significantly 255 different among the 4 groups (log rank test p<0.001), corresponding time-to-event curves are 256 presented in Figure 1 . 257 In adjusted Cox regression model, we found more than a 5-fold increase in the hazard of death 258 (hazard ratio (HR) 5.34, 95%-CI 3.37-8.44) associated with COVID-19 at admission, and more than 259 a 6-fold increase associated with hs-cTnT elevations at admission (HR 6.65, 95%-CI 3.86-11.46). 260 These associations remained after mutual adjustment for admission diagnosis and hs-cTnT 261 elevation, with a HR of 6.41 (95%-CI 4.05-10.14) for COVID-19 and 8.01 (95%-CI 4.64-13.82) for 262 hs-cTnT elevation, respectively ( Table 4) (Table S7) . 273 Four deaths (3.4%) occurred in Influenza patients (rate 0.9 per 100 patients per week, 95%-CI 0.3-274 2.2) as compared with 67 deaths (16.5%) among COVID-19 patients (rate 4.6 per 100 patients per 275 week, 95% CI 3.6-5.8), for an unadjusted HR of 5.23 (95%-CI 1.91 to 14.35). 276 In patients with Influenza, all deaths were recorded among patients with baseline hs-cTnT >14 ng/L 277 (rate 1.40 per 100 patients per week, 95%-CI 0.53-3.75). 278 In patients with COVID-19, 56 deaths occurred among those with hs-cTnT elevations (rate 8.59 per 279 100 patients per week, 95%-CI 6.61-11.16), whereas 11 deaths occurred in those without hs-cTnT 280 elevations (rate 1.36 per 100 patients per week, 95%-CI 0.75-2.46). Corresponding time-to-event 281 curves are presented in Figure S2 while Tables There are several limitations to this study. The prospective inclusion of influenza patients 386 was originally conceived as stand-alone cohort. Immediately after the COVID-19 outbreak, 387 measurement of myocardial injury in the same hospitalized settings was implemented as part of the 388 standard of care, but the data was only retrospectively collected after receiving institutional review 389 board approval during the first wave pandemic. There were differences in baseline characteristics 390 between hospitalized Influenza and COVID-19 patients. However, after accounting them in 391 multiple multivariable analysis models, results remained consistent. However, we cannot exclude 392 16 that covariates which were unmeasured might have biased our results. In particular, the decision to 393 hospitalize a patient with COVID-19 might have reflected not only the severity of presentation but 394 also the limited hospital capacity during the first COVID-19 pandemic wave. However, it is 395 reassuring that the frequency of myocardial injury at presentation was in fact lower among COVID-396 19 as compared with influenza patients. Older age and renal insufficiency have been described as 397 being associated with increased troponin levels even in the absence of concomitant viral infections, 398 thus their relationship with virally mediated myocardial injury might not be mechanistic but 399 potentially mediated by the role of several comorbidities 37 . Nonetheless as no standard definition 400 exists on alternative thresholds for myocardial biomarkers in specific subgroups of patients (e.g. 401 elderly, chronic kidney disease, multiple comorbidities), the single hs-TnT cut-off has been used. 402 As no standard definition exists for how much rise and/or fall of hs-cTn concentration should be 403 used to identify acute injury, our data cannot ultimately define the acute vs chronic nature of 404 observed cardiac injury. In patients with available repeated measurements, variations observed in 405 both cohorts are close to a relative change ±20% to the baseline value, that has been proposed as a 406 cut-off able to identify acute vs chronic myocardial, 407 Nonetheless, from a clinical perspective, the independent association with short term 408 mortality observed in both cohorts strengthens the prognostic utility of increased troponin levels 409 independently from an acute vs chronic nature of myocardial injury. Cardiac imaging is not 410 available in our data, as most patients were evaluated with informal point-of-care ultrasound. This Tables Table 1. Baseline clinical characteristics, laboratory values and outcome data in consecutive hospitalized patients with Influenza by presence of myocardial injury. <0.001 Weighted analyses done after multiple imputation, with weights defined as the inverse probability of the admission diagnosis to adjust analyses for differences in clinical and laboratory characteristics at admission between COVID-19 and Influenza patients. Deep phenotyping of 34,128 adult patients hospitalised 430 with COVID-19 in an international network study Zhong 435 NS, China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in 436 China Cardiovascular 438 Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, 442 China Seasonal Influenza Infections and 444 Cardiovascular Disease Mortality Fish 446 KM. Comorbidities, sequelae, blood biomarkers and their associated clinical outcomes in the Mount Sinai 447 Health System COVID-19 patients Ovidius Study G. High-sensitivity cardiac troponin T predicts mortality after 453 hospitalization for community-acquired pneumonia Elevated high-sensitivity 457 cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive 458 pulmonary disease Elevated Troponin in 460 Patients With Coronavirus Disease 2019: Possible Mechanisms Clinical features of patients infected with Characteristics and clinical significance of myocardial injury in patients with severe coronavirus 467 disease 2019 Prevalence and Impact of Myocardial 471 Injury in Patients Hospitalized With COVID-19 Infection Association of Troponin Levels With Mortality in Italian Patients 477 Hospitalized With Coronavirus Disease 2019: Results of a Multicenter Study Interactions of Influenza and SARS-CoV-2 with the Lung Endothelium: 482 Similarities, Differences, and Implications for Therapy Acute cardiac injury events